All In Biotech

Drug Trial Radar · NCT01373983

Intrathecal Bolus Doses of Ziconotide

Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study

Last checked: Nov 20, 2026Latest source record: Dec 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Aug 2011

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
University Hospital, LinkoepingAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 15, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if the effect of ziconotide can be tested by intrathecal bolus doses.

Conditions

  • Peripheral Neuropathy

Interventions

  • ZiconotideDrug

    1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Visual Analogue Scale Pain Intensity, VASPI, 0-100 mmTime frame: VASPI before injection and then each hour after injection, for 6 hours.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pain and Rehabilitation Centre, University Hospital

    Linköping, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.